OGT unveils reliable somatic CNV detection for CLL with new NGS panel

Oxford, UK – 13 January 2020. OGT, A Sysmex Group Company, is excited to announce the launch of its SureSeq™ CLL + CNV Panel — the company’s latest high-quality, next-generation sequencing (NGS) offering for research into Chronic Lymphocytic Leukaemia (CLL). The SureSeq CLL + CNV Panel fulfils the desire for reliable copy number variation (CNV) detection by NGS, including trisomy 12 and loss of heterozygosity (LOH), as well as somatic variants, even at low allele frequency. The panel, which has been tested to show excellent concordance with array data, can detect both small and large CNVs at 10% minor allele frequency (MAF), SNVs and indels down to 1% MAF and LOH at 5-10Mb.

The comprehensive panel covers all the most up-to-date, evidence-based genes and genomic aberrations for CLL and will enable laboratories to simplify their laboratory workflow by replacing multiple assays with a single one.

CLL is the most common type of leukaemia in adults and is associated with chromosomal aberrations ranging from somatic variants, to small and large CNVs, including trisomies. This complex genetic heterogeneity combined with a lack of sensitive and reliable NGS solutions has meant that currently scientists need to employ multiple methods to build a genomic profile of CLL samples.

One area in particular where NGS has traditionally struggled, is in the detection of CNVs, which can occur in important tumour suppressor genes, such as TP53. Additional techniques such as microarray, karyotyping or fluorescence in situ hybridisation (FISH) are often required to detect these CNVs and structural abnormalities, such as loss of heterozygosity (LOH) and trisomy 12.

The SureSeq CLL + CNV Panel was designed in collaboration with recognised cancer experts, as Emma Shipstone, Executive VP Marketing at OGT, highlights: “Having input from experienced cancer labs was instrumental in getting the design of the SureSeq CLL + CNV Panel spot on. This is CNV detection done well, yielding excellent data quality. This one assay can now replace the multiple assays historically necessary for the genomic profiling of CLL samples.”

For researchers, the single NGS panel simplifies the workflow and consolidates the profiling of the wide variety of genomic changes into a single analysis. Reliable data analyses can be carried out with OGT’s popular and easy-to-use Interpret software, a complementary and powerful software solution for accurate identification and visualisation of all variants including CNVs.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell^®, CytoSure^® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

For more information on the Company, please visit our website at ogt.com

CytoSure^®, SureSeq™ and myProbes^®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.